SCHEMBL8288

SCHEMBL8288

O=C(O)C1=NSc2ccccc2C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
POLB P06746 1/20 0.37
ALDH1A1 P00352 7/20 0.36
KDM4E B2RXH2 3/20 0.36
HPGD P15428 3/20 0.36
SRD5A2 P31213 2/20 0.34
RYR2 Q92736 1/20 0.34
LMNA P02545 2/20 0.33
NOTUM Q6P988 2/20 0.33
TRPA1 O75762 1/20 0.32
TSHR P16473 2/20 0.31
DAO P14920 1/20 0.31
NAPRT Q6XQN6 1/20 0.31
ALOX15 P16050 1/20 0.31
GSR P00390 1/20 0.31
BCHE P06276 1/20 0.31
ACHE P22303 1/20 0.31
GAA P10253 1/20 0.31
SMN1; SMN2 Q16637 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3619022 0.84 ALDH1A1 (0.36) MAOAMAOBPOLBALDH1A1KDM4E
SCHEMBL5836008 0.84 ALDH1A1 (0.35) MAOAMAOBALDH1A1KDM4EHPGD
SCHEMBL7382465 0.84 ALDH1A1 (0.37) MAOAMAOBPOLBALDH1A1KDM4E
SCHEMBL6542435 0.83 CA2 (0.34) ALDH1A1KDM4EHPGDLMNA
SCHEMBL6542401 0.80 TRPA1 (0.39) POLBALDH1A1KDM4EHPGDRYR2
SCHEMBL7974791 0.80 BCHE (0.38) ALDH1A1LMNATSHRALOX15BCHE
SCHEMBL7984059 0.79 TRPA1 (0.38) POLBALDH1A1KDM4EHPGDRYR2
Pyrrole SCHEMBL11735098 0.77 ALDH1A1 (0.32) ALDH1A1KDM4EHPGDGAA
SCHEMBL4103011 0.73 ALDH1A1 (0.37) ALDH1A1KDM4EHPGDLMNAMAPT
SCHEMBL3081411 0.72 ALDH1A1 (0.38) MAOAMAOBALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1289558-A2 COMBINATIONS OF AN ENDOTHELIN RECEPTOR ANTAGONIST AND AN ANTIEPILEPTIC COMPOUND HAVING PAIN ALLEVIATING PROPERTIES OR ANALGESIC WARNER-LAMBERT COMPANY LLC (US) 2003-03-12 EP claimed
US-6440962-B2 CARDIOVASCULAR DISORDERS, ANTIISCHEMIC AGENTS WARNER-LAMBERT COMPANY 2002-08-27 US claimed
US-20020094980-A1 Certain benzothiazine dioxide endothelin antagonists and processes for their preparation BUNKER AMY MAE (US) 2002-07-18 US claimed
WO-2001091736-A2 COMBINATIONS OF AN ENDOTHELIN RECEPTOR ANTAGONIST AND AN ANTIEPILEPTIC COMPOUND HAVING PAIN ALLEVIATING PROPERTIES OR ANALGESIC WARNER-LAMBERT COMPANY (US) 2001-12-06 WO claimed
US-20010036944-A1 Certain benzothiazine dioxide endothelin antagonists and processes for their preparation BUNKER AMY MAE (US) 2001-11-01 US claimed
EP-1009743-A1 CERTAIN BENZOTHIAZINE DIOXIDE ENDOTHELIN ANTAGONISTS AND PROCESSES FOR THEIR PREPARATION WARNER-LAMBERT COMPANY (US) 2000-06-21 EP claimed
WO-1999012916-A1 CERTAIN BENZOTHIAZINE DIOXIDE ENDOTHELIN ANTAGONISTS AND PROCESSES FOR THEIR PREPARATION WARNER-LAMBERT COMPANY (US) 1999-03-18 WO claimed
EP-0267432-B1 ANTIBACTERIALLY ACTIVE PYRIDO-BENZOTHIAZINE DERIVATIVES WITH LONG TERM ACTION MEDIOLANUM FARMACEUTICI s.r.l. (IT) 1991-12-27 EP claimed
EP-2499146-B1 TRICYCLIC PYRAZOL AMINE DERIVATIVES MERCK SERONO SA (CH) 2016-09-21 EP disclosed
CN-102695710-B Tricyclic pyrazole sulfonamide derivatives MERCK SERONO S.A. (CH) 2015-08-19 CN disclosed
US-9073940-B2 Tricyclic pyrazol amine derivatives MERCK SERONO SA (CH) 2015-07-07 US disclosed
CN-102695710-A Tricyclic pyrazol amine derivatives MERCK SERONO SA 2012-09-26 CN disclosed
US-20120238545-A1 TRICYCLIC PYRAZOL AMINE DERIVATIVES MERCK SERONO SA (CH) 2012-09-20 US disclosed
EP-2499146-A1 TRICYCLIC PYRAZOL AMINE DERIVATIVES Merck Serono S.A. (CH) 2012-09-19 EP disclosed
US-20030232787-A1 Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic DOOLEY DAVID JAMES (US) 2003-12-18 US disclosed
US-6545150-B2 Preparing 1,1-dioxo-2-phenyl-3-carboxy-4-phenyl-1,2-benzo(e)-thiazines by a five-step process starting with a (2-(methyl-oxycarbonyl-)phenyl-sulfonamido-)benzene; alkylation; cyclization; hydroxylation; esterification and coupling WARNER-LAMBERT COMPANY 2003-04-08 US disclosed
US-20010036944-A1 Certain benzothiazine dioxide endothelin antagonists and processes for their preparation BUNKER AMY MAE (US) 2001-11-01 US disclosed
EP-1009743-A1 CERTAIN BENZOTHIAZINE DIOXIDE ENDOTHELIN ANTAGONISTS AND PROCESSES FOR THEIR PREPARATION WARNER-LAMBERT COMPANY (US) 2000-06-21 EP disclosed
WO-1999012916-A1 CERTAIN BENZOTHIAZINE DIOXIDE ENDOTHELIN ANTAGONISTS AND PROCESSES FOR THEIR PREPARATION WARNER-LAMBERT COMPANY (US) 1999-03-18 WO disclosed
US-4529725-A 1-Pyridine substituted quino-benzothiazine ABBOTT LABORATORIES (US) 1985-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238545-A1 TRICYCLIC PYRAZOL AMINE DERIVATIVES PI4KB, MTOR, PI4KA MAOA 1857/4885MAOB 1446/4885POLB 1156/4885
US-20020094980-A1 Certain benzothiazine dioxide endothelin antagonists and processes for their preparation ECE1, EDNRA, EDNRB MAOA 2238/4885MAOB 2337/4885POLB 4045/4885
US-20010036944-A1 Certain benzothiazine dioxide endothelin antagonists and processes for their preparation ECE1, EDNRA, EDNRB MAOA 2238/4885MAOB 2337/4885POLB 4045/4885
US-20030232787-A1 Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic EDNRA, EDNRB, ECE1 MAOA 2589/4885MAOB 2636/4885POLB 4459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.